Convergent Bioscience Ltd.

Convergent Bioscience Ltd. specializes in precision diagnostics and analytical instruments for the biopharmaceutical sector, providing innovative solutions to enhance research and development processes. Convergent Bioscience Ltd. focuses on developing advanced biological and diagnostic technologies.

In October 2010, the company was acquired by Cell Biosciences for USD 12 mn in cash. The company is headquartered in Toronto, Canada. Convergent Bioscience Ltd. develops and supplies high-quality analytical instruments and diagnostics tailored for the biopharmaceutical industry.

Their primary offerings include advanced systems for protein analysis, aiding clients in areas such as monoclonal antibody development and regulatory compliance. Convergent Bioscience Ltd. generates revenue through direct sales of its analytical systems and reagents, primarily engaging in B2B transactions with biopharmaceutical firms. Their business model is reinforced by service agreements and customer training programs, ensuring effective product utilization and client support.

Convergent Bioscience plans to expand its product lineup with new innovative diagnostic tools and systems slated for release in the coming year. They aim to penetrate new geographic markets in Europe and Asia by 2025. The recent funding from their acquisition will be utilized to bolster research and development efforts, supporting these expansion strategies.